1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Informed Consent Form
   Response - Clinical Study Report
   
   
3. Who will be able to view these files?
   Response - Researchers who provide a methodologically sound proposal.
   


4. For what types of analyses will this data be available?
   Response - For individual participant data meta-analysis.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [hipreeti20@gmail.com].
   


6. For how long will this data be available start date provided 01-03-2022 and end date provided 31-12-2029?
   Response - Immediately following publication. No end date.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - nil

Goals of neuroanaesthesia are to provide good operating conditions and to ensure stable cerebral haemodynamics without sudden increase in intracranial pressure or acute brain swelling.

Furthermore, rapid recovery from anaesthesia is often required to allow immediate post operative neurological evaluation.

Anaesthesia is a balance between the amount of anaesthetic drug administered and the state of arousal of the patient. Patient movement in response to noxious stimulation remains an important sign of inadequatedepth of anaesthesia, but is unreliable and suppressed by paralysis.Traditional clinical signs such as hypertension, tachycardia, diaphoresis and lacrimation are unreliable indicators of DOA.

Depth of anaesthesia is a simplified construct of hypnosis, amnesia, antinociception and reflex suppression. A widely used method to measure inhaled anaesthetic requirement is the minimum alveolar concentration (MAC) of inhaled anaesthetic at which movement in response to nociceptive stimulus is suppressed in 50% of subjects at standard temperature and  pressure.

Most current proprietary depth of anaesthesia monitors such as Bispectral Index (BIS, Aspect Medical System, Newton, NA, USA) and Spectral Entropy (GE healthcare, Helsinki, Finland) use dimensionless monotonic index as ba measure of anaesthetic depth.

Dexmedetomidine, the pharmacologically active of isomer of medetomidine,  is a highly selective and specific α-2 adrenoceptor agonist.

Dexmedetomidine by its central sympatholytic action, promotes haemodynamic stability when used as an adjuvant during general anaesthesia. It has analgesic and anaesthetic sparing property.

However, because of its sedative property, it is unknown if the recovery from anaesthesia would be delayed when used as an continuous infusion.

The Bispectral Index(BIS) is an electroencephalogram (EEG)-derived parameter to monitor the hypnotic effects of anaesthetics.

BIS is shown to correlate well with the level of sedation produced by propofol and to accurately predict loss of consciousness.

Despite the various limitations inherent to all brain function monitors using processed EEG signals, very recent publications have confirmed the role of the BIS monitor (Medtronic, Minneapolis,MN, USA) as one of the commercially available standard devices to monitor brain function for depth of anaesthesia.